Phase II Vanguards Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.

Phase II Vanguards Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.
Cyntegrity logo – Risk-Based Quality Management Solutions

Understanding the Phase II Landscape

Phase II Vanguards is an interactive visualizer designed to help professionals understand who is advancing investigational therapies during the most uncertain stage of clinical development. It brings together trial, sponsor, and disease-level information into a single, interpretable view.

 

The visualizer exists to support learning and informed interpretation of Phase II activity—where early clinical promise is tested and many programs either progress or stop. By focusing on smaller and independent organizations, it highlights parts of the clinical research ecosystem that are often less visible but strategically important.

What You Can Explore With the Visualizer

Key ways the visualizer supports understanding of Phase II clinical trial activity:

Explore emerging Phase II sponsors

Gain visibility into companies, institutions, and research groups conducting Phase II studies outside the largest pharmaceutical organizations. This helps clarify who is driving development activity at this critical stage.

Understand disease and therapeutic focus

See how Phase II trials are distributed across therapeutic areas and indications. The visual structure makes it easier to recognize areas of concentration and emerging research themes.

Track trial progress and status

Review how studies are progressing, where they are located, and their current status. This supports a more grounded understanding of development momentum across the Phase II landscape.

About the Visual Approach

The Phase II Vanguards visualizer is based on structured data extracted from ClinicalTrials.gov, covering Phase II studies conducted between 2021 and 2023. Trials are filtered to include sponsors not affiliated with the top 100 pharmaceutical companies, allowing for focused analysis of independent and smaller-scale development efforts. The visual design emphasizes comparison, context, and pattern recognition rather than exhaustive detail.

 

Curious how Phase II activity is evolving across sponsors and indications?

Use the visualizer to explore relationships, trends, and trial characteristics at your own pace.

Part of the eyesON Interactive Visualizer Series

The eyesON series is Cyntegrity’s collection of interactive data visualizers created to support understanding through transparent, well-structured data exploration. These tools are developed as learning resources, making complex datasets more accessible without oversimplifying them.

 

Through the eyesON series, Cyntegrity shares its data analytics expertise and regulatory knowledge with the broader research community. Each visualizer transforms dense guidance and datasets into meaningful visual narratives that support learning, cross-functional dialogue, and practical understanding. Explore More Interactive Visualizers…

Explore Our Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.

Stay Informed with Us

Risk-Based Quality Management in Medical Devices: ISO 14155 vs ICH E6(R3)

Medical device investigations are now assessed like RBQM trials. Learn how ISO 14155 and ICH E6(R3) align and download the practical translation guide....

From spreadsheets to Digital RACT | ICH E6(R3) compliance

Learn why spreadsheet-based RACT falls short of ICH E6(R3) and how Digital RACT in the MyRBQM Portal delivers traceable, inspection-ready risk governance....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

Discover Expert Interviews & Podcasts on Clinical Innovation

Explore short interviews and podcast episodes with industry experts discussing RBQM, Clinical Operations, Data Science, and the future of clinical trials.

New episodes added regularly